Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson's disease

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Chen, Jiang Fan ^a,b   Fredduzzi, Silva ^a,c   Bastia, Elena ^a,c   Yu, Liqun ^a,b   Moratalla, Rosario ^d   Ongini, Ennio ^c   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c San Raffaele Science Park   (Italy)

^d INSTITUTO CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; AMPHETAMINE; LEVODOPA; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ISTRADEFYLLINE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; DYSKINESIA; MOUSE; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG TOLERANCE; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; NERVE CELL; PATHOPHYSIOLOGY; SYNAPSE;

AMPHETAMINE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; DRUG TOLERANCE; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MICE; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PURINES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; SYNAPSES; TRIAZOLES;

EID: 0345168894     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095218.26363.7b     Document Type: Article

References (80)

1. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord 1989;4:S126-144.
2. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-1053.
3. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-1143.
4. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999;14:911-913.
5. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:S17-25.
6. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-7.
7. Hagan JJ, Middlemiss DN, Sharpe PC, Poste GH. Parkinson's disease: prospects for improved drug therapy. Trends Pharmacol Sci 1997;18:156-163.
8. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2001;8:101-108.
9. Chase TN, Konitsiotis S, Oh JD. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol 2001;86:355-360.
10. Chase TN, Oh JD, Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000;47:S122-129; discussion S129-130.
11. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000;247(suppl 2):II43-50.
12. Ferre S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience 1992;51:501-512.
13. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
14. Ongini E, Fredholm BB. Pharmacology of adenosine A2A receptors, Trends Pharmacol Sci 1996;17:364-372.
15. Latini S, Pazzagli M, Pepeu G, Pedata F. A2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Gen Pharmacol 1996;27:925-933.
16. Pollack AE, Fink JS. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res 1996;743:124-130.
17. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H: Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys, Neurology 1999;52:1673-1677.
18. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
19. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
20. Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 1998;9:2857-2860.
21. Morelli M, Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 2001;22:71-72.
22. Pinna A, di Chiara G, Wardas J, Morelli M. Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats. Eur J Neurosci 1996;8:1176-1181.
23. Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 2001;39:233-238.
24. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
25. Mori A, Shindou T, Ichimura M, Nonaka H, Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996;16:605-611.
26. Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
27. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol 1996;48:167-189.
28. Svenningsson P, Johansson B, Fredholm BB. Caffeine-induced expression of c-fos mRNA and NGFI-A mRNA in caudate putamen and in nucleus accumbens are differentially affected by the N-methyl-D-aspartate receptor antagonist MK-801. Brain Res Mol Brain Res 1996;35:183-189.
29. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 1999;59:355-396.
30. Chen JF, Moratalla R, Impagnatiello F, et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 2001;98:1970-1975.
31. Norenberg W, Wirkner K, Assmann H, Richter M, Illes P. Adenosine A2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons. Amino Acids 1998;14:33-39.
32. Golembiowska K, Zylewska A. Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res 1998;806:202-209.
33. Okada M, Mizuno K, Kaneko S. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 1996;212:53-56.
34. Martinez-Mir MI, Probst A, Palacios JM. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991;42:697-706.
35. Carey RJ. Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res 1991;568:205-214.
36. Henry B, Crossman AR, Brotchie JM. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Adv Neurol 1998;78:53-61.
37. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-342.
38. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 1999;155:204-220.
39. Brotchie JM, Henry B, Hille CJ, Crossman AR. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Adv Neurol 1998;78:41-52.
40. Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002;22:1054-1062.
41. Marin C, Engber TM, Bonastre M, Chase TN, Tolosa E. Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior. Brain Res 1996;731:57-62.
42. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996;736:202-205.
43. Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 2003;84:1398-1410.
44. Chen J-F, Moratalla R, Turner T, et al. Deficiency of the A2a adenosine receptor attenuates striatal dopamine release as well as spontaneous and amphetamine-induced locomotion. Presented at the 28th annual meeting of the Society for Neuroscience; 1998; Los Angeles.
45. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63.
46. Chen J-F, Moratalla R, Yu L-Q, et al. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology 2003;28:1086-1095.
47. El Yacoubi M, Ledent C, Parmentier M, Daoust M, Costentin J, Vaugeois J. Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 2001;40:424-432.
48. Shimazoe T, Yoshimatsu A, Kawashimo A, Watanabe S. Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization. Eur J Pharmacol 2000;388:249-254.
49. Okada M, Kiryu K, Kawata Y, et al. Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. Eur J Pharmacol 1997;321:181-188.
50. Zetterstrom T, Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 1990;180:137-143.
51. Dassesse D, Massie A, Ferrari R, et al. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 2001;78:183-198.
52. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998;54:679-720.
53. Marchi M, Raiteri L, Risso F, et al. Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol 2002;136:434-440.
54. Popoli P, Betto P, Reggio R, Ricciarello G. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 1995;287:215-217.
55. Bonci A, Williams JT. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 1996;16:631-639.
56. Fiorillo CD, Williams JT. Selective inhibition by adenosine of mGluR IPSPs in dopamine neurons after cocaine treatment. J Neurophysiol 2000;83:1307-1314.
57. Harvey J, Lacey MG. A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 1997;17:5271-5280.
58. Manzoni O, Pujalte D, Williams J, Bockaert J. Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J Neurosci 1998;18:7996-8002.
59. O'Regan MH, Simpson RE, Perkins LM, Phillis JW. The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Lett 1992;138:169-172.
60. Moratalla R, Elibol B, Vallejo M, Graybiel AM. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron 1996;17:147-156.
61. Nestler EJ, Barrot M, Self DW. DeltaFosB: a sustained molecular switch for addiction. Proc Natl Acad Sci USA 2001;98:11042-11046.
62. Svenningsson P, Lindskog M, Ledent C, et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA 2000;97:1856-1860.
63. Wirkner K, Assmann H, Koles L, et al. Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents in rat neostriatal neurons. Br J Pharmacol 2000;130:259-269.
64. Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000;23: S86-91.
65. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001;4:873-874.
66. Swanson CJ, Baker DA, Carson D, Worley PF, Kalivas PW. Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer. J Neurosci 2001;21:9043-9052.
67. Diaz-Cabiale Z, Vivo M, Del Arco A, et al. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett 2002;324:154-158.
68. Kearney JA, Albin RL. Adenosine A2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation. Eur J Pharmacol 1995;287:115-120.
69. Kearney JA, Becker JB, Frey KA, Albin RL. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience 1998;87:881-891.
70. Kearney JA, Frey KA, Albin RL. Metabotropic glutamate agonist-induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study. J Neurosci 1997;17:4415-4425.
71. Popoli P, Pezzola A, Torvinen M, et al. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Neuropsychopharmacology 2001;25:505-513.
72. d'Alcantara P, Ledent C, Swillens S, Schiffmann SN. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 2001;107:455-464.
73. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501-506.
74. Lindskog M, Svenningsson P, Fredholm BB, Greengard P, Fisone G. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience 1999;88:1005-1008.
75. Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999;6:461-474.
76. Andersson M, Westin JE, Cenci MA. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 2003;17:661-666.
77. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10:2694-2706.
78. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118.
79. Herrero MT, Augood SJ, Hirsch EC, et al. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995;68:1189-1198.
80. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.